VEGFA and neoplasm: In essence, the dual-target combination increases Ivonescimab’s retention in the tumor microenvironment, further enhancing its anti-tumor activity and achieving an effect where 1 + 1 > 2.VEGF: vascular endothelial growth factor; PD-1:programmed death-1; PD-L1:programmed death ligand 1; Treg: T regulatory cell; MDSC: myeloid-derived suppressor cell; CTL: Cytotoxic T lymphocytes; TCR: T cell receptor; Ag: antigen.